Advertisement

Advertisement

IOVA Stock Latest News

Joseph Pantginis Maintains Buy Rating on Iovance as AMTAGVI’s Global Expansion and Survival Data Support Unchanged $9 Price Target

RatingsJoseph Pantginis Maintains Buy Rating on Iovance as AMTAGVI’s Global Expansion and Survival Data Support Unchanged $9 Price Target

Iovance receives Australian approval of Amtagvi for advanced melanoma

PremiumThe Fly

Iovance receives Australian approval of Amtagvi for advanced melanoma

2d ago

Iovance gets allowance to proceed from FDA for IOV-5001 IND application

PremiumThe Fly

Iovance gets allowance to proceed from FDA for IOV-5001 IND application

4d ago

Iovance’s Terminated TIL Study Reshapes Expectations for Solid-Tumor Growth

PremiumCompany Announcements

Iovance’s Terminated TIL Study Reshapes Expectations for Solid-Tumor Growth

21d ago

Iovance Biotherapeutics Signals Strong Momentum in Call

PremiumCompany Announcements

Iovance Biotherapeutics Signals Strong Momentum in Call

28d ago

Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan

PremiumThe FlyIovance Biotherapeutics price target lowered to $14 from $16 at Chardan

29d ago

Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)

The Fly

Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)

29d ago

Iovance Biotherapeutics sees Q2 revenue $86M-$88M, consensus $84.36M

The Fly

Iovance Biotherapeutics sees Q2 revenue $86M-$88M, consensus $84.36M

29d ago

Iovance Biotherapeutics sees FY26 revenue $350M-$370M, consensus $359.68M

PremiumThe Fly

Iovance Biotherapeutics sees FY26 revenue $350M-$370M, consensus $359.68M

29d ago

Unusually active option classes on open May 6th

PremiumThe Fly

Unusually active option classes on open May 6th

29d ago

Iovance Biotherapeutics (IOVA) Q1 Earnings Cheat Sheet

PremiumPre-Earnings

Iovance Biotherapeutics (IOVA) Q1 Earnings Cheat Sheet

1M ago

Replimune CRL positive for Iovance in near-term, says Chardan

PremiumThe Fly

Replimune CRL positive for Iovance in near-term, says Chardan

2M ago

Iovance could advance 5%-15% on Replimune rejection, says Jefferies

PremiumThe FlyIovance could advance 5%-15% on Replimune rejection, says Jefferies

2M ago

Unusually active option classes on open April 10th

The Fly

Unusually active option classes on open April 10th

2M ago

Iovance Biotherapeutics Announces Upcoming Board Member Retirement

Company Announcements

Iovance Biotherapeutics Announces Upcoming Board Member Retirement

3M ago

Iovance Biotherapeutics call volume above normal and directionally bullish

PremiumThe Fly

Iovance Biotherapeutics call volume above normal and directionally bullish

3M ago

Iovance Biotherapeutics price target raised to $4 from $2 at UBS

PremiumThe Fly

Iovance Biotherapeutics price target raised to $4 from $2 at UBS

3M ago

Iovance Biotherapeutics Signals Strong Momentum In Earnings

PremiumCompany Announcements

Iovance Biotherapeutics Signals Strong Momentum In Earnings

3M ago

Iovance Biotherapeutics price target raised to $4 from $3 at Baird

PremiumThe Fly

Iovance Biotherapeutics price target raised to $4 from $3 at Baird

3M ago

Iovance Biotherapeutics price target raised to $11 from $10 at Barclays

PremiumThe FlyIovance Biotherapeutics price target raised to $11 from $10 at Barclays

3M ago

Iovance upgraded to Outperform from Market Perform at Citizens

The Fly

Iovance upgraded to Outperform from Market Perform at Citizens

3M ago

Iovance Biotherapeutics price target lowered to $16 from $17 at Chardan

The Fly

Iovance Biotherapeutics price target lowered to $16 from $17 at Chardan

3M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >